Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
ITM Solucin GmbH
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
GlaxoSmithKline
St. Jude Children's Research Hospital
University of Wisconsin, Madison
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hutchmed
University of Virginia
University Hospital, Basel, Switzerland
Bayer
National Cancer Institute (NCI)
Bristol-Myers Squibb
Case Comprehensive Cancer Center
Children's Hospitals and Clinics of Minnesota
Novartis
National Institutes of Health Clinical Center (CC)
Masonic Cancer Center, University of Minnesota
SillaJen, Inc.